| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 04/11/2002 | CA2424117A1 Phosphoric acid salt of an integrin receptor antagonist |
| 04/11/2002 | CA2423929A1 Carbohydrate-associated proteins |
| 04/11/2002 | CA2423888A1 Hydroxyesters of 7-desmethylrapamycin |
| 04/11/2002 | CA2423677A1 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 04/11/2002 | CA2423312A1 Condensed pyridoindole derivatives |
| 04/11/2002 | CA2421417A1 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/10/2002 | EP1195605A1 Methods and compositions for screening modulators of lipid kinases |
| 04/10/2002 | EP1195604A1 Methods and compositions for screening modulators of lipid kinases |
| 04/10/2002 | EP1195435A1 Truncated phosphodiesterase-7 polypeptides |
| 04/10/2002 | EP1194567A1 Production of complex carbohydrates |
| 04/10/2002 | EP1194557A2 An interleukin-1 receptor antagonist and uses thereof |
| 04/10/2002 | EP1194546A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 04/10/2002 | EP1194448A1 Seven transmembrane receptor genes |
| 04/10/2002 | EP1194443A1 Cysteinyl protease inhibitors |
| 04/10/2002 | EP1194425A1 Substituted benzimidazole |
| 04/10/2002 | EP1194422A1 Biaryl compounds |
| 04/10/2002 | EP1194411A1 Benzoylpyridazines |
| 04/10/2002 | EP1194401A1 Diacylhydrazine derivatives |
| 04/10/2002 | EP1194167A1 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 04/10/2002 | EP1194157A1 D-form polypeptide which induces immune tolerance and methods of use |
| 04/10/2002 | EP1194152A1 Src kinase inhibitor compounds |
| 04/10/2002 | EP1194151A1 Integrin receptor antagonists |
| 04/10/2002 | EP1194143A2 Il-8 receptor antagonists |
| 04/10/2002 | EP1030845B1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 04/10/2002 | EP0950046B1 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators |
| 04/10/2002 | EP0935458B1 Compositions containing at least one nucleic acid |
| 04/10/2002 | EP0927150B1 Lipoxin compounds and their use in treating cell proliferative disorders |
| 04/10/2002 | CN1344326A Petroviral vectors comprising functional and non-functional splice donor and splce acceptor sites |
| 04/10/2002 | CN1344266A Novel compounds |
| 04/10/2002 | CN1344249A 酰胺衍生物 Amide derivatives |
| 04/10/2002 | CN1344247A Multicyclic compounds which inhibit beukocyte adhesion mediated by VLA-4 |
| 04/10/2002 | CN1344160A Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 04/10/2002 | CN1344159A Combinations for treatment of diseases involving angiogenesis |
| 04/10/2002 | CN1344155A Transnasal transport/immunisation with highly adaptable carriers |
| 04/10/2002 | CN1082378C Externally-used arthralgia treating medicine and its prepn. method |
| 04/09/2002 | US6369210 22012, human carboxypeptidase |
| 04/09/2002 | US6369107 Combined use of diclofenac and tribenoside to treat osteoarthritis |
| 04/09/2002 | US6369099 Method of locking 1 α-OH of vitamin D compounds in axial orientation |
| 04/09/2002 | US6369089 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists |
| 04/09/2002 | US6369084 Prostaglandin mediated diseases |
| 04/09/2002 | US6369082 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 04/09/2002 | US6369077 Protease inhibitors |
| 04/09/2002 | US6369029 Method of stimulating osteogenesis using a c-terminally truncated insulin-like growth factor binding protein-5 (IGFBP-5) |
| 04/09/2002 | US6368787 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 04/09/2002 | CA2298572C Deuterated cyclosporine analogs and their use as immunomodulating agents |
| 04/09/2002 | CA2249744C Oral peptide pharmaceutical products |
| 04/04/2002 | WO2002027318A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | WO2002026976A1 Uses of the gjb6 gene for treating certain types of alopecia including the clouston's syndrome, and for screening compounds capable of being efficient in the treatment of alopecia with genetic susceptibility |
| 04/04/2002 | WO2002026954A2 Truncated phosphodiesterase-7 polypeptides |
| 04/04/2002 | WO2002026946A2 Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
| 04/04/2002 | WO2002026935A2 TGF-β INHIBITORS AND METHODS |
| 04/04/2002 | WO2002026929A2 Kini-3 motor protein and methods for its use |
| 04/04/2002 | WO2002026833A1 Compositions and methods for the endocytic presentation of immunosuppressive factors |
| 04/04/2002 | WO2002026825A2 G-protein coupled receptors |
| 04/04/2002 | WO2002026782A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 04/04/2002 | WO2002026781A2 Ige receptor antagonists |
| 04/04/2002 | WO2002026774A2 Melanocortin receptor ligands |
| 04/04/2002 | WO2002026737A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| 04/04/2002 | WO2002026733A2 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 04/04/2002 | WO2002026722A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| 04/04/2002 | WO2002026717A2 Hydroxy acid integrin antagonists |
| 04/04/2002 | WO2002026706A2 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
| 04/04/2002 | WO2002026704A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | WO2002026258A2 Treatment of immune-mediated diseases by oral administration of plasma fractions |
| 04/04/2002 | WO2002026256A1 Excessive antibody production inhibitors, process for producing the same and method of using the same |
| 04/04/2002 | WO2002026245A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| 04/04/2002 | WO2002026227A1 Lactone integrin antagonists |
| 04/04/2002 | WO2002026214A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | WO2002014281A8 Pyridine derivatives as inhibitors of p38 |
| 04/04/2002 | WO2002000167A3 Modified forms of pharmacologically active agents and uses therefor |
| 04/04/2002 | WO2001097837A8 Solubilised protein vaccines |
| 04/04/2002 | WO2001097795A3 Systems and methods for treating a mucosal surface |
| 04/04/2002 | WO2001094347A8 Tetracyclic diketopiperazine compounds as pdev inhibitors |
| 04/04/2002 | WO2001089451A3 Protease inhibitors |
| 04/04/2002 | WO2001081332A3 2-fluorobenzenesulfonyl compounds for the treatment of inflammation |
| 04/04/2002 | WO2001080841A3 Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis |
| 04/04/2002 | WO2001073034A3 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 04/04/2002 | WO2001073033A3 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 04/04/2002 | WO2001053353A3 Recombinant antibodies to human interkleukin-1 beta |
| 04/04/2002 | WO2001048231A3 Method of achieving persistent transgene expression |
| 04/04/2002 | US20020040149 EP4 receptor selective agonists in the treatment of osteoporosis |
| 04/04/2002 | US20020040135 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them |
| 04/04/2002 | US20020040051 Solid dispersion of ipriflavone for oral administration and its manufacturing methods |
| 04/04/2002 | US20020040039 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 04/04/2002 | US20020040030 Derivatives of 3-(pyrimidin-5- yl)- and 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro(1,8) naphthyridin-2-yl)-nonanoic acid useful for inhibiting bone resorptin, restenosis, angiogenesis, diabetic retinopathy etc |
| 04/04/2002 | US20020040022 Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection |
| 04/04/2002 | US20020040020 Substituted pyrazoles |
| 04/04/2002 | US20020040019 Substituted pyrazoles |
| 04/04/2002 | US20020040002 Hydroxamic acids substituted by heterocycles useful for inhibition of tumor necrosis factor |
| 04/04/2002 | US20020039599 Calibration; administering antiseptic compound |
| 04/04/2002 | US20020039567 Wound healing agent; genetic engineering |
| 04/04/2002 | DE10045591A1 Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) Site-specific, antibody-mediated activation of proapoptotic cytokines - Amaize (Antibody Mediated Apoptosis Inducing cytokines) |
| 04/04/2002 | CA2426666A1 Ion-strength independent sustained release pharmaceutical formulation |
| 04/04/2002 | CA2426117A1 Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation |
| 04/04/2002 | CA2423955A1 Kini-3 motor protein and methods for its use |
| 04/04/2002 | CA2423889A1 Methods and compositions for screening modulators of lipid kinases |
| 04/04/2002 | CA2423805A1 Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin g |
| 04/04/2002 | CA2423704A1 G-protein coupled receptors |
| 04/04/2002 | CA2423474A1 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents |
| 04/04/2002 | CA2423464A1 Hydroxy acid integrin antagonists |